Press Releases

Jun 18

Solid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of Directors

CAMBRIDGE, Mass. , June 18, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced today the appointment of board member Ian F. Smith as Chairman of the Board. Mr.

Read More
May 22

Solid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16, 2020

CAMBRIDGE, Mass. , May 22, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced that, due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, its 2020 Annual Meeting

Read More
May 14

Solid Biosciences Presents Data from Duchenne Muscular Dystrophy Gene Therapy Program at ASGCT 23rd Annual Meeting

Virtual oral presentation reviews interim clinical biomarker data for SGT-001 and provides data on expression and co-localization of microdystrophin and dystrophin associated proteins in patients in the IGNITE DMD trial Virtual poster presentation provides data characterizing novel adeno-associated

Read More
May 07

Solid Biosciences Provides Update regarding SGT-001 Phase I/II Clinical Hold on IGNITE DMD

CAMBRIDGE, Mass. , May 07, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced that it received written communication from the U.S.

Read More
Apr 16

Solid Biosciences Announces Appointment of Ian F. Smith to its Board of Directors

Smith to Deepen Strategic Leadership and Complement Commercial, Operational and Financial Expertise of the Board CAMBRIDGE, Mass. , April 16, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular

Read More
Mar 12

Solid Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

– Biopsy results from the third patient dosed at 2E14 vg/kg in the SGT-001 IGNITE DMD clinical trial provide further support for continued development – – Solid continues to make progress to address the IGNITE DMD clinical hold and advance the next steps for the SGT-001 program – CAMBRIDGE, Mass.

Read More
Jan 09

Solid Biosciences Announces Organizational Changes to Prioritize Development of SGT-001

CAMBRIDGE, Mass. , Jan. 09, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced changes to its organizational structure to create a leaner company focused on advancing SGT-001, a gene transfer candidate for the treatment of Duchenne muscular dystrophy (Duchenne).

Read More

News & Events

Press Releases

Solid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of Directors

Solid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16, 2020

Solid Biosciences Presents Data from Duchenne Muscular Dystrophy Gene Therapy Program at ASGCT 23rd Annual Meeting

Solid Biosciences Provides Update regarding SGT-001 Phase I/II Clinical Hold on IGNITE DMD

Solid Biosciences Announces Appointment of Ian F. Smith to its Board of Directors

Solid Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

Solid Biosciences Announces Organizational Changes to Prioritize Development of SGT-001